News und Analysen
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best
QIAGEN führt Workflow-Configurator zur Vereinfachung und Optimierung von Laborexperimenten im Life-Sciences-Bereich ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung des Workflow-Configurator bekannt. Die Anwendung unterstützt forschende Wissenschaftler, indem sie die Suche nach
Humana Hiring up to 200 Seasonal Positions in Louisville
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced it is looking to hire up to 200 seasonal Enrollment Representatives in and around Louisville.
Humana’s Medicare
Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2021 financial results after market close on Thursday, July 29, 2021. Management will hold a conference call
QUANTUM GENOMICS : Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant high
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2021, the Compensation Committee (the “Compensation Committee”) of Puma’s Board of Directors approved
Chemed To Report Second-Quarter 2021 Earnings July 27, Related Conference Call To Be Held On July 28
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2021, on Tuesday, July 27, 2021, following the close of trading on the New
AMN Healthcare to Sponsor Float in Ticker-Tape Parade Honoring COVID-19 Essential Workers
AMN Healthcare, the leader and innovator of healthcare talent solutions, will sponsor a float in a classic New York City ticker-tape parade honoring COVID-19 essential workers on Wednesday, July 7
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
ICON plc, (NASDAQ: ICLR) (“ICON”) today announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a labeling supplement to the U.S. Prescribing Information
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Novocure (NASDAQ: NVCR) today announced final results from its phase 2 pilot HEPANOVA trial in liver cancer testing the safety and efficacy of Tumor Treating Fields (TTFields) together with
QIAGEN bildet strategische Allianz mit Sysmex Corporation – Ziel ist die globale Entwicklung und Vermarktung von Begleitdiagnostika für Krebserkrankungen basierend auf NGS- und Plasma-Safe-SeqS-Technologie
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine globale strategische Allianz mit der japanischen Sysmex Corporation (Börse Tokio, erster Handelsabschnitt [Ticker-Code: 6869])
QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global strategic alliance with Japan’s Sysmex Corporation (Tokyo Stock Exchange, First Section [Ticker Code: 6869]) for the
Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced dose
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Bronson Healthcare Partners With Acadia Healthcare to Build New Behavioral Health Hospital to Serve Southwest Michigan
Bronson Healthcare and Acadia Healthcare Company announced today that they have formed a joint venture to build a 96-bed inpatient behavioral health facility in Battle Creek, Michigan. Together
Acadia Healthcare Forms Joint Venture with Bronson Health to Build a New Behavioral Health Facility in Southwest Michigan
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Bronson Healthcare, one of Michigan’s leading, integrated healthcare systems. The new
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) today announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006120/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
QIAGEN geht Partnerschaft mit Verogen ein und bietet nun das umfassendste Portfolio an Produkten für die Personenidentifizierung, darunter NGS-Sequenzierungslösungen
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine Vermarktungspartnerschaft mit Verogen bekannt gegeben, einem in San Diego ansässigen Spezialisten für Forensik. Kunden beider
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a commercialization partnership with San Diego-based human identification specialist Verogen that will provide customers of
Humana Ranked No. 1 Among Health Insurers for Customer Experience
Humana ranked No. 1 among Health Insurers for customer experience (CX) quality in Forrester’s proprietary 2021 US CX Index™ survey. The ranking was based on responses from more than 85,000 US
TA Instruments Helps Laboratories Automate Thermal Analysis Workflows with New TRIOS AutoPilot Software
Waters Corporation (NYSE:WAT) today introduced TRIOS AutoPilot software from its TA Instruments Division for its thermal analyzer product line. The software helps laboratory staff using TA’s